Patent · US Active

Matrix metalloproteinase (MMP) inhibitors and methods of use thereof

US11673884B2 · kind B2 · utility

0Cited by
2References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 13, 2020
Grant dateJun 13, 2023
Priority date—
Expiry dateFeb 21, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Y304/24065
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Hydantoin based compounds of formula (I) useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.